Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;16(2):92-7.
doi: 10.1097/MOH.0b013e3283257b18.

Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?

Hervé Dombret  1 , Claude Preudhomme, Nicolas Boissel
Affiliations
Review

Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?

Hervé Dombret et al. Curr Opin Hematol. 2009 Mar.

Abstract

Purpose of review: Core binding factor acute myeloid leukemia (CBF-AML) corresponds to two distinct subtypes of AML characterized by recurrent favorable chromosome translocations, namely t(8;21) and inv(16)/t(16;16). Given the relatively good outcome of patients with CBF-AML, when treated with intensive chemotherapy including high-dose cytarabine, they are generally not considered as candidates for intensification with allogeneic stem cell transplantation in the first complete remission. The optimal treatment strategy (place of stem cell transplantation, best postremission chemotherapy, role of targeted agents) remains, however, to be defined in these patients.

Recent findings: The biological and prognostic heterogeneity of both CBF-AML subtypes, including gene mutation and gene expression profiles as well as molecular response to therapy, has been recently described.

Summary: These new insights in the heterogeneity of CBF-AML suggest that a tailored approach might be preferred to a unique predefined strategy to treat these patients.

PubMed Disclaimer

Comment in

  • Myeloid disease.
    Tallman MS. Tallman MS. Curr Opin Hematol. 2009 Mar;16(2):63. doi: 10.1097/MOH.0b013e3283279a76. Curr Opin Hematol. 2009. PMID: 19468265 No abstract available.